Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 19/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16402312 | 0.98 | NR4A1 (0.53) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL2480936 | 0.98 | NR4A1 (0.53) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16402393 | 0.85 | NR4A1 (0.50) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6127791 | 0.84 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1038671 | 0.84 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1037346 | 0.84 | NR4A1 (0.49) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL511504 | 0.84 | NR4A1 (0.49) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21195190 | 0.84 | NR4A1 (0.49) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL16923575 | 0.83 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7822005 | 0.82 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-22 | — | — | US | disclosed |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| EP-2958919-B1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-2958919-B1 | DIHYDROPTERIDINONES I | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| EP-3004079-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | ACTURUM REAL ESTATE AB (SE) | 2018-01-17 | — | — | EP | disclosed |
| EP-3004081-B1 | TRIAZOLE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | ACTURUM REAL ESTATE AB (SE) | 2017-11-15 | — | — | EP | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009073777-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009032277-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-2019093-A1 | UREA TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
| WO-2008153792-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | NR4A1 162/4885PSEN1 3275/4885PSEN2 3796/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | NR4A1 530/4885PSEN1 3/4885PSEN2 6/4885 |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | MKI67, HDGF, PCLAF | NR4A1 2639/4885PSEN1 4398/4885PSEN2 4353/4885 |
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | NR4A1 2639/4885PSEN1 4398/4885PSEN2 4353/4885 |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | NR4A1 2639/4885PSEN1 4398/4885PSEN2 4353/4885 |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | APP, BACE1, BACE2 | NR4A1 542/4885PSEN1 7/4885PSEN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.